









Markets
/
Stocks
/
nasdaq-sndl
/

SNDL Inc

SNDL

2.560USD

+0.060+2.40%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

658.82MMarket Cap

LossP/E TTM



SNDL Inc

2.560

+0.060+2.40%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

61 / 175

Overall Ranking

176 / 4721

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

4.064

Target Price

+62.57%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

SNDL Inc. is a Canada-based private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf, and Firesale Cannabis. The Company is a licensed cannabis producer and a vertically integrated cannabis companies in Canada specializing in low-cost biomass sourcing, premium indoor cultivation, product innovation, low-cost manufacturing facilities, and a cannabis brand portfolio that includes Top Leaf, Contraband, Palmetto, Bon Jak, Versus, Value Buds, and Vacay. Its segments include Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. Liquor retail includes the sale of wines, beers and spirits through owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis through owned and franchise retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 21.77% year-on-year.

Undervalued

The company’s latest PE is -6.86, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 52.81M shares, increasing 12.37% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 392.79K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.63.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 9.08, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 179.88M, representing a year-over-year increase of 7.85%, while its net profit experienced a year-over-year increase of 150.24%.

Score

Industry at a Glance

Previous score

9.08

Change



Financials

9.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.25

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.40

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.57

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -6.70, which is -74.55% below the recent high of -1.71 and 36.00% above the recent low of -4.29.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 61/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for SNDL Inc is 4.06, with a high of 4.50 and a low of 3.63.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

4.064

Target Price

+62.57%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

SNDL Inc

SNDL

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 8.82, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 2.80 and the support level at 2.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.82

Change

-0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.047

Neutral

RSI(14)

66.039

Neutral

STOCH(KDJ)(9,3,3)

76.353

Buy

ATR(14)

0.119

Low Volatility

CCI(14)

87.291

Neutral

Williams %R

39.474

Buy

TRIX(12,20)

0.890

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.494

Buy

MA10

2.451

Buy

MA20

2.460

Buy

MA50

2.009

Buy

MA100

1.659

Buy

MA200

1.664

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 20.52%, representing a quarter-over-quarter increase of 24.47%. The largest institutional shareholder is Invesco, holding a total of 392.79K shares, representing 0.15% of shares outstanding, with 50.24% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cannell (James Carlo)

9.17M

Cannell Capital, LLC

8.99M

-11.61%

Tidal Investments LLC

7.09M

+11.56%

BNP Paribas Securities Corp. North America

4.52M

+9.85%

Millennium Management LLC

515.82K

+170.18%

Morgan Stanley Investment Management Inc. (US)

2.17M

+101.06%

Mirae Asset Global Investments (USA) LLC

1.97M

-5.90%

Global X Investments Canada Inc.

1.96M

-0.37%

George (Zachary R)

1.71M

+151.72%

Morgan Stanley & Co. LLC

1.00M

-24.68%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.31, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 3.83. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.